Urology · Stress Urinary IncontinenceTrial Updateclinicalmid-term

Study on Tactile Feedback Training for Stress Urinary Incontinence in Pregnant Women

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/29/2026, 6:30:58 PM

Assessment confidence: 67% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

This clinical trial could redefine treatment protocols for stress urinary incontinence in pregnant women, potentially leading to a shift in clinical practice. If tactile feedback training is proven more effective, it may create new market opportunities for therapeutic devices in women's health. Regulatory context from PMDA ([IBENTO][IBENTO]The report for the PMDA Asia office GMP Workshop Training 2026 has been posted.) supports the near-term read. Assessment grounded in 20 ranked evidence items (10 high-relevance).

Strategic Assessment

If tactile feedback proves more effective, it may lead to a shift in clinical practice and open opportunities for new therapeutic devices or interventions in women's health. The strongest clinical anchor is Tactile Feedback Pelvic Floor Training to Prevent Stress Urinary Incontinence in the 3rd Trimester of Pregnancy (ClinicalTrials.gov), moderate corpus alignment. In Urology · Stress Urinary Incontinence, 4 regulatory and 4 competitive items passed relevance filtering for pelvic floor therapy solutions.

Competitive Pressure

The most relevant competitive pressure comes from Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from Phase 3 Study of Radiprodil in GRIN-related Neurodevelopmental Disorder Initiated. This study could influence treatment protocols for stress urinary incontinence during pregnancy, potentially impacting market dynamics for pelvic floor therapy solutions.

Regulatory Outlook

Regulatory risk is concentrated around [IBENTO][IBENTO]The report for the PMDA Asia office GMP Workshop Training 2026 has been posted. Moderate corpus alignment. Relevant agencies in corpus: PMDA, FDA. Depending on trial outcomes, new therapeutic devices may require regulatory approval, affecting compliance timelines and market entry strategies.

Key Risks

Elevated medium regulatory exposure for pelvic floor therapy solutions could delay market entry or constrain labeling if agency review intensifies.
Clinical risk from ClinicalTrials.gov (Stress, Coping, and Sleep Health Study) could weigh on pelvic floor therapy solutions through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

A shift in treatment efficacy could influence market share for existing pelvic floor therapy solutions and create demand for new interventions, impacting revenue streams.
Upside for pelvic floor therapy solutions may improve if MedlyPeds Feasibility Study (ClinicalTrials.gov) delivers favorable follow-through.
If tactile feedback proves more effective, it may lead to a shift in clinical practice and open opportunities for new therapeutic devices or interventions in women's health.

What Would Change This Assessment

This becomes more urgent if Monitor trial results and publication of findings, particularly regarding the effectiveness of tactile feedback compared to traditional methods.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

[IBENTO][IBENTO]The report for the PMDA Asia office GMP Workshop Training 2026 has been posted.
PMDAhigh relevance
Moderate corpus alignment
FDA document
View source
Compounding Quality Center of Excellence | Instructor-Led Trainings
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
Compounding Quality Center of Excellence | Self-Guided Online Trainings
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
ClinicalTrials.gov: Essentials for Academic Medical Centers - 07/14/2026
FDAhigh relevance
Moderate corpus alignment
FDA document
View source

Tactile Feedback Pelvic Floor Training to Prevent Stress Urinary Incontinence in the 3rd Trimester of Pregnancy
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
Pelvic Pain in Women With Endometriosis
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Trial of an Online Spanish Pivotal Response Treatment Training in Autism Spectrum Disorder
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Utero-ovarian Transposition in Patients With Pelvic Malignancies Undergoing Whole Pelvic Radiotherapy
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
MedlyPeds Feasibility Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Tirzepatide in the Treatment of Cannabis Use Disorder: A Proof-of-Concept Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Stress, Coping, and Sleep Health Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Phase 3 Study of Radiprodil in GRIN-related Neurodevelopmental Disorder Initiated
Humanexa Signalsmedium relevance
Moderate corpus alignment
UK-wide ENDO1000 Study Aims to Advance Endometriosis Diagnosis and Treatment
Humanexa Signalsmedium relevance
Moderate corpus alignment
Study on Air Pollution's Impact on Cystic Fibrosis Severity in Hispanic Children
Humanexa Signalsmedium relevance
Moderate corpus alignment

Do subjective and objective baseline sleep disturbances predict post-traumatic stress disorder treatment response? A secondary analysis of a randomized controlled trial.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
A 3.6:1 myo-inositol to D-chiro-inositol ratio and antioxidant-based food supplement before IVF improves fertility in women with PCOS: a pilot observational retrospective cohort study.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
12‑weeks fisetin supplementation and interval resistance with aerobic training: changes in Maresin‑1 and inflammatory markers in men with obesity: a randomized controlled trial.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

pelvic floor therapy solutions

Commercial impact

medium

A shift in treatment efficacy could influence market share for existing pelvic floor therapy solutions and create demand for new interventions, impacting revenue streams.

Regulatory impact

medium

Depending on trial outcomes, new therapeutic devices may require regulatory approval, affecting compliance timelines and market entry strategies.

What to watch

Monitor trial results and publication of findings, particularly regarding the effectiveness of tactile feedback compared to traditional methods.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.